TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR
Sponsors
Merck Sharp & Dohme LLC, Gilead Sciences Inc., Ospedale Pediatrico Bambino Gesu, Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Conditions
HIVHIV-1 Infectionperinatally HIV infection
Phase 2
A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-Daily
CompletedCTIS2024-511041-19-00
Start: 2021-04-06End: 2025-01-28Target: 48Updated: 2025-01-29
A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily in Treatment-Naïve Adult Participants Living With HIV 1
Not yet recruitingCTIS2025-522519-40-00
Target: 35Updated: 2026-02-16
Phase 3
A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
Active, not recruitingCTIS2024-514047-28-00
Start: 2025-01-27Target: 98Updated: 2025-09-12
The Italian Cohort (ITACO) and the Analytical Antiretroviral Treatment Interruption Italian Cohort (ITACO-ATI) study guided by molecular HIV-1 reservoir profiling
RecruitingCTIS2024-518694-33-00
Start: 2023-08-08Target: 61Updated: 2025-07-24